| Document |
Document Title |
|
WO/2023/148203A1 |
The invention relates to a pharmaceutical composition comprising a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting aft...
|
|
WO/2023/145959A1 |
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3...
|
|
WO/2023/147134A2 |
The present disclosure relates generally to a method of treating post-traumatic stress disorder, schizophrenia, acute stress disorder, anxiety, depression, or bone loss comprising administration of a neurokinin (NK) receptor antagonist t...
|
|
WO/2023/143741A1 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/145619A1 |
This non-enveloped virus inactivation composition comprises: (a) a positive ion surfactant; (b) at least one selected from (b1) aliphatic alcohols having a cLogP of 0.80-2.40 and (b2) aromatic alcohols having a cLogP of 1.4-2.0; and water.
|
|
WO/2023/146211A1 |
The present invention relates to granules comprising Progerinin, capsules or sachets using same, and a preparation method therefor. More specifically, in order to develop a formulation that is advantageous when applying, to patients, Pro...
|
|
WO/2023/145792A1 |
The purpose of the present invention is to provide a technique for effectively suppressing microorganism growth in a composition for oral use and the like. The present invention relates to a composition containing (A) L-ergothioneine or ...
|
|
WO/2023/144326A1 |
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...
|
|
WO/2023/146341A1 |
The present invention relates to: an ovarian anti-aging pharmaceutical composition comprising, as an active ingredient, a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof; an ovarian anti-aging method comprisi...
|
|
WO/2023/145530A1 |
This therapeutic agent for cancer contains a compound that acts on a retinoid receptor and a BRAF inhibitor. The therapeutic agent for cancer is for use alongside a BRAF inhibitor, and contains a compound that acts on a retinoid receptor...
|
|
WO/2023/147107A1 |
Provided herein are antibody agents that bind specifically to Activin A, as well as compositions comprising Activin A antibody agents, and methods of making and using the same.
|
|
WO/2023/145844A1 |
Provided is a substance demonstrating an anti-tumor effect by introducing changes in a tumor microenvironment (TME), including inhibition or suppression of TME formation. This invention relates to an anti-human CXCL1 antibody including d...
|
|
WO/2023/143112A1 |
Disclosed are a salt form and a crystal form of an azabenzo eight-membered ring compound and an application thereof. Specifically disclosed are a crystal form A, crystal form B, crystal form C, and crystal form D of fumarate salt, hydroc...
|
|
WO/2023/147468A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...
|
|
WO/2023/145833A1 |
Provided is a mutant MAD7 protein demonstrating enhanced breakage activity to a target site. This mutant MAD7 protein contains an amino acid sequence B resulting from mutation of an amino acid sequence A with Sequence Number 1, the amino...
|
|
WO/2023/145812A1 |
The present invention provides a glycosylated protein having glucocerebrosidase activity. This glycosylated protein having glucocerebrosidase activity is obtained by adding a sugar chain having a single structure to an unglycosylated pro...
|
|
WO/2023/140355A1 |
[Problem] Provided is a cancer treatment drug that suppresses the proliferation of cancer cells. [Solution] This cancer treatment drug contains a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/140524A1 |
The present invention relates to an antifibrotic inhibitory composition, and to: a pharmaceutical composition for preventing or treating liver fibrosis, comprising, as an active ingredient, a peptide derived from a stem cell culture solu...
|
|
WO/2023/140350A1 |
The present invention provides a pharmaceutical composition for suppressing organ fibrosis, characterized by having an angiotensin II receptor antagonist as an active ingredient, and being administered at a dosage of 0.2 times or less th...
|
|
WO/2023/139626A1 |
Interoception is the mechanism by which an individual is informed about the status of its own body. When interoception becomes dysfunctional, it turns into a deleterious event for the health status of an individual. The use of calcitonin...
|
|
WO/2023/140329A1 |
A medicine for treating or preventing cancer, the medicine comprising a first active ingredient used together with a second active ingredient, the first active ingredient being a compound expressed by formula (1) or a salt thereof or a s...
|
|
WO/2023/140664A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating liver fibrosis induced by non-alcoholic steatohepatitis, containing, as an active ingredient, an expression inhibitor of lipocalin 2 or a receptor ...
|
|
WO/2023/139581A1 |
Compounds represented by Formula I: (I) wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula la, lb, III, IV or V, as defined in the instant specification, and uses thereof in modulating an ac...
|
|
WO/2023/140242A1 |
The present disclosure provides a composition for protecting a tissue isolated from a living body, said composition containing a compound of formula (I) or an ester, oxide, prodrug, pharmaceutically acceptable salt or solvate of the same.
|
|
WO/2023/140309A1 |
[Problem] To elucidate the mechanism of an anti-tumor effect of a ketogenic diet therapy to discover a novel cancer treatment method. [Solution] Provided is a composition for treating cancer, the composition comprising a ketogenic diet t...
|
|
WO/2023/140308A1 |
The present invention addresses the problem of providing a novel composition for the proliferation of Akkemansia muciniphila present in the intestinal flora. The composition for the proliferation of Akkemansia muciniphila contains plat...
|
|
WO/2023/139187A1 |
Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclos...
|
|
WO/2023/136342A1 |
The present invention provides a cyclic peptide represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, A is selected from ring-forming groups A1-A5; Xaa1 is a residue of an aromatic amino acid; Xaa2 is...
|
|
WO/2022/136851A9 |
The present invention relates to the use of a reduced folate, such as 5-MTHF (5- methyltetrahydrofolate), optionally in combination with tetrahydrobiopterin (BH4) or precursors thereof, for preventing or treating disorders associated wit...
|
|
WO/2023/136279A1 |
Provided are a crystal of a compound represented by formula (I) that can be used as an active pharmaceutical ingredient of a drug, salts of the compound represented by formula (I), and crystals thereof.
|
|
WO/2023/135150A1 |
Provided herein are methods of administering different GHB forms on different days for the treatment of narcolepsy, IH, EDS and other conditions.
|
|
WO/2023/136313A1 |
A purpose of the present invention is to provide a means for treating a hepatic function disorder. The aforementioned problem is solved by, for example: a composition for treating a hepatic function disorder or for ameliorating a hepatic...
|
|
WO/2023/135978A1 |
Provided is a drug for treating aftereffects of a novel coronavirus infection. The drug for treating aftereffects of the novel coronavirus infection contains an acetylcholine receptor agonist as an active ingredient.
|
|
WO/2023/136329A1 |
The present invention provides: a cell proliferation retardant which contains D-allose and/or a derivative thereof and/or a mixture of D-allose and a derivative thereof as an active ingredient and which prolongs a period retaining in the...
|
|
WO/2023/136151A1 |
The present invention addresses the problem of providing a novel ASMT expression promoter and provides an ASMT expression promoter that contains, as an active ingredient, at least one substance selected from the group consisting of eucal...
|
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
|
WO/2023/135533A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: Formula (I) wherein R is chosen from • - phenyl, a 6-membered heteroaryl group, cyclohexyl, a 5- membered heteroaryl group; • ...
|
|
WO/2023/131866A1 |
The present disclosure relates to the treatment of transfusion dependence and anemia in patients with myelodysplastic syndrome (MDS). The present disclosure relates to methods of using novel biomarkers to treat transfusion dependence and...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/133386A1 |
The present disclosure relates to methods and compositions for oral delivery of nutrients and/or pharmaceuticals, particularly for tissue repair and regeneration of the body, and more particularly to methods and compositions for protecti...
|
|
WO/2023/133576A1 |
Hydration of a larynx and/or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and/or NaCl) can achieve prophylactic and/or therapeutic effects (e.g., cough suppression, improving voice quality, increasin...
|
|
WO/2023/127600A1 |
The present invention addresses the problem of providing a novel drug for treating SITH-1-associated diseases. The problem is solved by a drug for treating SITH-1-associated diseases, the drug containing a cholinergic agonist as an activ...
|
|
WO/2023/127907A1 |
The present invention addresses the problem of avoiding an immune response caused by gene transfection. The present inventors have found, after intensive studies to solve the above problem, that it is possible to avoid apoptosis due to i...
|
|
WO/2023/127645A1 |
Disclosed is an exosome including, in a lipid bilayer, at least one exosome marker protein selected from CD63, CD81, and CD9 and integrin α and/or integrin β. This exosome enables drug delivery with high target selectivity.
|
|
WO/2023/127961A1 |
According to the present invention, provided is a composition for inducing satiety or suppressing overeating. This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provid...
|
|
WO/2023/123468A1 |
Provided in the present invention are a cardiovascular and cerebrovascular drug and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein each group is defined as desc...
|
|
WO/2023/126076A1 |
The present invention relates to an amide of γ-hydroxybutyric acid for medical use in the treatment of Fragile X Syndrome and to a pharmaceutical composition containing this derivative mixed with a physiologically acceptable carrier. Th...
|
|
WO/2023/127888A1 |
A new peptide and a pharmaceutical composition comprising the peptide were provided.
|
|
WO/2023/128597A1 |
The present invention relates to a physiological saline which includes N,N,N-trimethyl chitosan, thus having the advantages of an excellent anti-adhesion effect as well as an excellent antibacterial or hemostatic effect.
|
